Compare AbCellera Biologics Inc (ABCL) vs Firy Inc. (FIRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Firy Inc. — how do they compare? AbCellera Biologics Inc trades at $9.94 (market cap $2.99B), while Firy Inc. trades at $10 (market cap $159.51M). The key difference: AbCellera Biologics Inc is far larger — about 18.7× Firy Inc.'s market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Firy Inc. nearer its low. Which is the better fit depends on your goals.
| ABCL | FIRY | |
|---|---|---|
Market Cap | $2.99B | $159.51M |
Sector | Health | Consumer Cyclical |
52-Week High | $9.76 | $12.45 |
52-Week Low | $2.78 | $2.28 |
Enterprise Value | $2.58B | $103.18M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABCL's stock rose 7.07% to $10.00, buoyed by positive Phase 2 trial results for its menopause drug ABCL635, which demonstrated an 83% reduction in hot flashes (Business Wire, August 10, 2026). Despite negative profitability margins and cash burn, technical indicators show a bullish trend with strong moving average support. The company maintains a solid balance sheet with $625.61 million in cash and low debt, though revenue declined from $485 million in 2022 to $75 million in 2025.
The outlook hinges on clinical success and monetization of ABCL635, with a consensus price target of $15.50 implying 55% upside. Key risks include prolonged cash burn, drug development setbacks, and competitive pressures. Analyst sentiment is overwhelmingly bullish (91.67% buy ratings), but investors must weigh high valuation multiples against unproven commercial traction.
FIRY trades at $9.98, down 4.77% in the last 24 hours, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q1 2026 revenue growth and a slight earnings beat, yet maintains negative net income margins and cash flow challenges. Recent news includes a legal victory awarding $719 million and a rebrand from Skillz Inc.
Outlook remains cautious due to persistent losses and cash burn, though the legal win provides a liquidity boost. Risks include high SG&A costs and competitive pressures, while analyst sentiment is mixed with a majority hold rating. Investors should weigh the potential from strategic shifts against fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →
